0001193125-20-286140.txt : 20201105 0001193125-20-286140.hdr.sgml : 20201105 20201105062156 ACCESSION NUMBER: 0001193125-20-286140 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20201105 FILED AS OF DATE: 20201105 DATE AS OF CHANGE: 20201105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MorphoSys AG CENTRAL INDEX KEY: 0001340243 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: 2M FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38455 FILM NUMBER: 201288512 BUSINESS ADDRESS: STREET 1: SEMMELWEISSTR. 7 CITY: PLANEGG STATE: 2M ZIP: 82152 BUSINESS PHONE: 49 89 89927-0 MAIL ADDRESS: STREET 1: SEMMELWEISSTR. 7 CITY: PLANEGG STATE: 2M ZIP: 82152 FORMER COMPANY: FORMER CONFORMED NAME: MORPHOSYS AG DATE OF NAME CHANGE: 20050929 6-K 1 d96183d6k.htm FORM 6-K Form 6-K

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF A FOREIGN ISSUER

PURSUANT TO RULE 13A-16 OR 15D-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For November 05, 2020

Commission File Number 1-38455

 

 

MorphoSys AG

 

 

Semmelweisstrasse 7

82152 Planegg

Germany

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ☐            No  ☒

If ‘‘Yes’’ is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):

 

 

 



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    MORPHOSYS AG (Registrant)
Date: November 05, 2020     By:  

/s/ ppa. Charlotte Lohmann

    Name:   Charlotte Lohmann
    Title:   General Counsel Legal, Compliance & IP
    By:  

/s/ i.A. Isabelle Degbegni

    Name:   Isabelle Degbegni
    Title:   Associate Director CC&IR
EX-99.1 2 d96183dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Conference Call Alert

Planegg/Munich, Germany, November 4, 2020

Invitation to MorphoSys’ Third Quarter and First 9-Month 2020 Results Conference Call on November 12, 2020

MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) will publish its results for the third quarter and first 9-month of 2020 on November 11, 2020 at 10:00pm CET (9:00pm GMT; 4:00pm EST).

MorphoSys’ Management team will host a conference call and webcast on November 12, 2020 at 2:00pm CET (1:00pm GMT; 8:00am EST) to present the third quarter and first 9-month financial results 2020 and the further outlook for 2020.

 

Date of the conference call:

  

Thursday, November 12, 2020

Time:

  

2:00pm CET (1:00pm GMT, 8:00am EST)

Dial-in numbers:

  

Germany:

  

+49 69 201 744 220

United Kingdom:

  

+44 203 009 2470

USA:

  

+1 877 423 0830

(all numbers reachable from any geography)

  

Participant PIN:

  

26740320#

Please dial in 10 minutes before the beginning of the conference.

A live webcast and slides will be made available at www.morphosys.com.

Approximately two hours after the call, a slide-synchronized audio replay of the conference and a transcript of the prepared remarks will be available on www.morphosys.com.

About MorphoSys

MorphoSys is a commercial-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 27 are currently in clinical development. In 2017, Tremfya®, developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc., for the treatment of plaque psoriasis, became the first drug based on MorphoSys’ antibody technology to receive regulatory approval. In July 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval of MorphoSys’ proprietary product Monjuvi® (tafasitamab-cxix) in combination with lenalidomide in patients with a certain type of lymphoma. Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has ~500 employees.

More information at www.morphosys.com or MorphoSys-US.com.

 

Page 1 of 3


Monjuvi® is a registered trademark of MorphoSys AG.

Tremfya® is a registered trademark of Janssen Biotech, Inc.

MorphoSys forward looking statements

This communication contains certain forward-looking statements concerning the MorphoSys group of companies, including the expectations regarding tafasitamab’s ability to treat patients with relapsed or refractory diffuse large B-cell lymphoma, the further clinical development of tafasitamab, including ongoing confirmatory trials, additional interactions with regulatory authorities and expectations regarding future regulatory filings and possible additional approvals for tafasitamab as well as the commercial performance of tafasitamab. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “would,” “could,” “potential,” “possible,” “hope” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys’ results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are MorphoSys’ expectations regarding risks and uncertainties related to the impact of the COVID-19 pandemic to MorphoSys’ business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products, the global collaboration and license agreement for tafasitamab, the further clinical development of tafasitamab, including ongoing confirmatory trials, and MorphoSys’ ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials, additional interactions with regulatory authorities and expectations regarding future regulatory filings and possible additional approvals for tafasitamab as well as the commercial performance of tafasitamab, MorphoSys’ reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys’ Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.

For more information, please contact:

MorphoSys

  Investor Contacts:

  Dr. Julia Neugebauer

  Director Corporate Communications & IR

  Tel: +49 (0) 89 / 899 27-179

  Julia.Neugebauer@morphosys.com

 

Page 2 of 3


  Media Contacts:

  Jeanette Bressi

  Director, US Communications

  Tel: +1 617-404-7816

  media@morphosys.com

  Sophie Petersen

  Senior Specialist

  Tel: +49 (0) 89 899 27 26033

  media@morphosys.com

 

Page 3 of 3

GRAPHIC 3 g96183img01.jpg GRAPHIC begin 644 g96183img01.jpg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end